IMV Researchers to Present New Preclinical Data at AACR Annual Meeting 2019
March 12 2019 - 6:05AM
Business Wire
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage
immuno-oncology company today announced that members of the
Company’s research and development team will present results from a
study at the American Association for Cancer
Research (AACR) Annual Meeting 2019, which is being held March
29 to April 3 in Atlanta, Georgia. The new preclinical research
highlights the unique features of DPX-based T cell
immunotherapies.
“The unique capabilities of our DPX-based platform and its
potential to fuel novel treatment approaches continue to drive
IMV’s robust research and development program,” said Marianne
Stanford, PhD, Vice President, Research and Development of IMV. “We
are looking forward to presenting additional insights into the way
our platform works, and its capacity for working with other
anti-cancer agents, at this year’s AACR annual meeting. This work
supports our goal of expanding the benefits of immunotherapies to a
wider range of patients and indications.”
Details of IMV’s AACR 2019 poster is as follows:
Session Category: ImmunologyAbstract Number:
4989Authors: Ava Vila-Leahey, Alecia MacKay, Genevieve Weir,
Marianne Stanford
Title: T-distributed stochastic neighbor embedding
(t-SNE) analysis of tumor infiltrating lymphocytes after treatment
with a T cell activating therapy identifies a unique population of
recruited CD8+ T cells and novel options for combination
immunotherapy
Date: Wednesday Apr 3, 2019Time: 8:00 a.m. -
12:00 p.m. ETLocation: Georgia World Congress Center,
Exhibit Hall B, Poster Section 24Poster Board Number: 12
Meeting abstracts are available at AACR's website.
About IMV
IMV Inc. is a clinical stage biopharmaceutical company dedicated
to making immunotherapy more effective, more broadly applicable,
and more widely available to people facing cancer and other serious
diseases. IMV is pioneering a new class of immunotherapies based on
the Company’s proprietary drug delivery platform. This patented
technology leverages a novel mechanism of action that enables the
programming of immune cells in vivo, which are aimed at
generating powerful new synthetic therapeutic capabilities. IMV’s
lead candidate, DPX-Survivac, is a T cell-activating immunotherapy
that combines the utility of the platform with a target: survivin.
IMV is currently assessing DPX-Survivac as a monotherapy in
advanced ovarian cancer, as well as a combination therapy in
multiple clinical studies with Merck. Connect
at www.imv-inc.com.
IMV Forward-Looking Statements
This press release contains forward-looking information under
applicable securities law. All information that addresses
activities or developments that we expect to occur in the future is
forward-looking information. Forward-looking statements are based
on the estimates and opinions of management on the date the
statements are made. In the press release, such forward-looking
statements include, but are not limited to, statements regarding
the FDA potentially granting accelerated regulatory approval of
DPX-Survivac. However, they should not be regarded as a
representation that any of the plans will be achieved. Actual
results may differ materially from those set forth in this press
release due to risks affecting the Corporation, including access to
capital, the successful design and completion of clinical trials
and the receipt and timely receipt of all regulatory
approvals. IMV Inc. assumes no responsibility to update
forward-looking statements in this press release except as required
by law. These forward-looking statements involve known and unknown
risks and uncertainties and those risks and uncertainties include,
but are not limited to, our ability to access capital, the
successful and timely completion of clinical trials, the receipt of
all regulatory approvals and other risks detailed from time to time
in our ongoing quarterly filings and annual information form
Investors are cautioned not to rely on these forward-looking
statements and are encouraged to read IMV’s continuous disclosure
documents, including its current annual information form, as well
as its audited annual consolidated financial statements which are
available on SEDAR at www.sedar.com and on EDGAR
at www.sec.gov/edgar.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190312005178/en/
Investor Relations:Marc Jasmin, IMV Senior Director,
Investor Relations and CommunicationsO: (902) 492-1819 ext: 1042M:
(514) 917-9481 E: mjasmin@imv-inc.com
Patti Bank, Managing Director, Westwicke PartnersO: (415)
513-1284M: (415) 515-4572 E: patti.bank@westwicke.com
Media:Andrea Cohen, Sam Brown Inc.O: (917) 209-7163
E: andreacohen@sambrown.com
IMV (TSX:IMV)
Historical Stock Chart
From Jun 2024 to Jul 2024
IMV (TSX:IMV)
Historical Stock Chart
From Jul 2023 to Jul 2024